Novartis Q4 Results
Content
Click below to navigate
through the document
Robust top and bottom-line growth during the quarter and FY
FINANCIAL PROFILE
↓
↑
Company overview
Financial review
Continuing operations¹
Q4
Change vs. PY
FY
Conclusions
USD million
2023
2023
% USD
% cc
% USD
Change vs. PY
% cc
Appendix
Net sales
11,423
8
10
45,440
8
10
References
Core operating income
3,821
5
13
16,372
11
18
Core margin
33.5%
1% pts
36.0%
2.4% pts
Operating income
2,582
47
68
9,769
23
39
Net Income
2,638
101
130
8,572
42
62
Core EPS (USD)
1.53
10
16
6.47
18
25
EPS (USD)
1.29
108
140
4.13
49
70
Free cash flow
2,141
-38
13,160
9
Novartis Q4 Results | January 31, 2024
27
1. As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities. Core results and
constant currencies are non-IFRS measures. Details regarding non-IFRS measures can be found starting on page 49 of the Condensed Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
□ NOVARTIS | Reimagining Medicine.View entire presentation